Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

GP2 peptide/GM-CSF vaccine

A vaccine containing a HER2/Neu-derived epitope (amino acids 654-662) (GP2), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activity. Upon vaccination, GP2 may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against HER2/Neu expressing cancer cells. GM-CSF may potentiate a tumor-specific cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the HER2/Neu antigen. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search